BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis

S Verstovsek, HK Al-Ali, J Mascarenhas… - Future …, 2022 - Taylor & Francis
Patients with myelofibrosis (MF) who discontinue ruxolitinib due to progression/resistance
have poor prognoses. JAK inhibitors control symptoms and reduce spleen volumes with …

The CXCR1/CXCR2 Inhibitor Reparixin Alters the Development of Myelofibrosis in the Gata1 low Mice

P Verachi, F Gobbo, F Martelli, A Martinelli… - Frontiers in …, 2022 - frontiersin.org
A major role for human (h) CXCL8 (interleukin-8) in the pathobiology of myelofibrosis (MF)
has been suggested by observations indicating that MF megakaryocytes express increased …

Bone marrow soluble mediator signatures of patients with philadelphia chromosome-negative myeloproliferative neoplasms

JG Cominal, MC Cacemiro, MG Berzoti-Coelho… - Frontiers in …, 2021 - frontiersin.org
Background Essential thrombocythemia (ET), polycythemia vera (PV), and primary
myelofibrosis (PMF) are clonal hematological diseases classified as Philadelphia …